BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: MDX-1100Biological: sterile saline for injection
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 110
- Registration Number
- NCT00656890
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Florida Medical Clinic-Tampa Clinic, Tampa, Florida, United States
🇺🇸Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT00655746
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT00651508
- Locations
- 🇺🇸
Consultants In Blood Disorders & Cancer, Louisville, Kentucky, United States
Drug Interaction Study
- Conditions
- Antivirals/HIV
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT00646776
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- Conditions
- Venous Thrombosis
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5614
- Registration Number
- NCT00643201
- Locations
- 🇺🇸
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
🇺🇸Great Falls Clinic, Llp, Great Falls, Montana, United States
🇺🇸Infectious Disease Of Indiana Psc, Carmel, Indiana, United States
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: BMS-641988 (AR#2)
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT00644488
- Locations
- 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan
Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: MDX-1342
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT00639834
- Locations
- 🇺🇸
Impact Clinical Trials, Los Angeles, California, United States
🇺🇸Good Samaritan Hospital and Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Coastal Medical Research, Inc, Port Orange, Florida, United States
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1211
- Registration Number
- NCT00636168
- Locations
- 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
🇺🇸The Angeles Clinic & Research Institute, Los Angeles, California, United States
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
- Conditions
- Hodgkin's Lymphomas
- Interventions
- Biological: MDX-1401
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00634452
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇺🇸ClinWorks Cancer Research Center, Charlotte, North Carolina, United States
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2711
- Registration Number
- NCT00633893
- Locations
- 🇺🇸
Mercury Street Medical Group, Pllc, Butte, Montana, United States
🇺🇸Piedmont Healthcare/Research, Statesville, North Carolina, United States
🇺🇸William Beaumont Hospital, Royal Oak, Michigan, United States